Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70


A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J.

Oncologist. 2019 Oct 8. pii: theoncologist.2019-0608. doi: 10.1634/theoncologist.2019-0608. [Epub ahead of print]


Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marté JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL.

J Immunother Cancer. 2019 Sep 5;7(1):240. doi: 10.1186/s40425-019-0706-x.


Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.

Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH.

Cancer Immunol Res. 2019 Aug;7(8):1359-1370. doi: 10.1158/2326-6066.CIR-18-0620. Epub 2019 Jul 10.


A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Aug 15;25(16):4933-4944. doi: 10.1158/1078-0432.CCR-19-0183. Epub 2019 May 20.


Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.

JCI Insight. 2019 Apr 4;4(7). pii: 126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.


Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.

Hamilton DH, McCampbell KK, Palena C.

Front Oncol. 2018 May 3;8:143. doi: 10.3389/fonc.2018.00143. eCollection 2018.


A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C.

Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.


Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.

Dominguez C, McCampbell KK, David JM, Palena C.

JCI Insight. 2017 Nov 2;2(21). pii: 94296. doi: 10.1172/jci.insight.94296.


Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Shah SR, David JM, Tippens ND, Mohyeldin A, Martinez-Gutierrez JC, Ganaha S, Schiapparelli P, Hamilton DH, Palena C, Levchenko A, Quiñones-Hinojosa A.

Cell Rep. 2017 Oct 10;21(2):495-507. doi: 10.1016/j.celrep.2017.09.057.


Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.


The adverse effect of overweight in assisted reproduction treatment outcomes.

Sampo AV, Palena C, Ganzer L, Maccari V, Estofán G, Hernández M.

JBRA Assist Reprod. 2017 Sep 1;21(3):212-216. doi: 10.5935/1518-0557.20170041.


Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Dominguez C, David JM, Palena C.

Semin Cancer Biol. 2017 Dec;47:177-184. doi: 10.1016/j.semcancer.2017.08.002. Epub 2017 Aug 18. Review.


Feline leukocyte adhesion (CD18) deficiency caused by a deletion in the integrin β2 (ITGB2) gene.

Bauer TR Jr, Pratt SM, Palena CM, Raj K, Giger U.

Vet Clin Pathol. 2017 Sep;46(3):391-400. doi: 10.1111/vcp.12526. Epub 2017 Jul 27.


Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.


Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.

Hamilton DH, David JM, Dominguez C, Palena C.

Cells Tissues Organs. 2017;203(2):128-138. doi: 10.1159/000446495. Epub 2017 Feb 20. Review.


Pharmacological and immunological targeting of tumor mesenchymalization.

David JM, Dominguez C, Palena C.

Pharmacol Ther. 2017 Feb;170:212-225. doi: 10.1016/j.pharmthera.2016.11.011. Epub 2016 Dec 1. Review.


Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.

Dominguez C, Tsang KY, Palena C.

Cell Death Dis. 2016 Sep 29;7(9):e2380. doi: 10.1038/cddis.2016.297.


Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

Hamilton DH, Roselli M, Ferroni P, Costarelli L, Cavaliere F, Taffuri M, Palena C, Guadagni F.

Endocr Relat Cancer. 2016 Oct;23(10):783-796. doi: 10.1530/ERC-16-0037.


The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance.

David JM, Dominguez C, Hamilton DH, Palena C.

Vaccines (Basel). 2016 Jun 24;4(3). pii: E22. doi: 10.3390/vaccines4030022. Review.


Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.

Hamilton DH, Griner LM, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M, Palena C.

Clin Cancer Res. 2016 Dec 15;22(24):6204-6216. Epub 2016 Jun 7.


IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C.

Oncotarget. 2016 Jul 5;7(27):42031-42044. doi: 10.18632/oncotarget.9662.


MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.

David JM, Hamilton DH, Palena C.

Oncoimmunology. 2016 Jan 6;5(4):e1117738. eCollection 2016 Apr.


The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, Schlom J.

Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.


Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.

Palena C, Hamilton DH.

Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12. Review.


Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.

Miettinen M, Wang Z, Lasota J, Heery C, Schlom J, Palena C.

Am J Surg Pathol. 2015 Oct;39(10):1305-12. doi: 10.1097/PAS.0000000000000462.


Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.

Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Dec;63(12):1307-17. doi: 10.1007/s00262-014-1603-2. Epub 2014 Sep 4.


Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.


Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.


WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.

Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C.

Cancer Res. 2014 May 1;74(9):2510-9. doi: 10.1158/0008-5472.CAN-13-1894. Epub 2014 Mar 13.


Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.

Cancer Res. 2014 Apr 1;74(7):1945-57. doi: 10.1158/0008-5472.CAN-13-2045. Epub 2014 Feb 11.


Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.


The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.

Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C.

Cell Death Dis. 2013 Jun 20;4:e682. doi: 10.1038/cddis.2013.208.


An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.

Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C.

Mol Cancer Ther. 2013 Sep;12(9):1805-15. doi: 10.1158/1535-7163.MCT-12-1007. Epub 2013 Jun 19.


Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR.

Int J Cancer. 2013 Aug 1;133(3):624-36. doi: 10.1002/ijc.28070. Epub 2013 Mar 16.


Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.

Palena C, Hamilton DH, Fernando RI.

Future Oncol. 2012 Jun;8(6):713-22. doi: 10.2217/fon.12.59. Review.


Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.

Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C.

Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.


Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.

Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C.

Semin Oncol. 2012 Jun;39(3):358-66. doi: 10.1053/j.seminoncol.2012.02.005. Review.


IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C.

Cancer Res. 2011 Aug 1;71(15):5296-306. doi: 10.1158/0008-5472.CAN-11-0156. Epub 2011 Jun 8.


Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.

Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J.

Exp Biol Med (Maywood). 2011 May 1;236(5):537-45. doi: 10.1258/ebm.2011.010367. Epub 2011 Mar 22. Review.


Vaccines against human carcinomas: strategies to improve antitumor immune responses.

Palena C, Schlom J.

J Biomed Biotechnol. 2010;2010:380697. doi: 10.1155/2010/380697. Epub 2010 Mar 16. Review.


Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.

Litzinger MT, Foon KA, Tsang KY, Schlom J, Palena C.

Leuk Res. 2010 Oct;34(10):1351-7. doi: 10.1016/j.leukres.2009.12.013. Epub 2010 Jan 31.


The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.

Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C.

J Clin Invest. 2010 Feb;120(2):533-44. doi: 10.1172/JCI38379. Epub 2010 Jan 11.


High rate of unintended pregnancy among pregnant women in a maternity hospital in Córdoba, Argentina: a pilot study.

Palena C, Bahamondes MV, Schenk V, Bahamondes L, Fernandez-Funes J.

Reprod Health. 2009 Jul 20;6:11. doi: 10.1186/1742-4755-6-11.


New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.

Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2010 Jan;59(1):63-71. doi: 10.1007/s00262-009-0723-6. Epub 2009 Jun 4.


Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.

Litzinger MT, Foon KA, Sabzevari H, Tsang KY, Schlom J, Palena C.

Cancer Immunol Immunother. 2009 Jun;58(6):955-65. doi: 10.1007/s00262-008-0611-5. Epub 2008 Nov 14.


Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.

Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.

Clin Cancer Res. 2008 May 15;14(10):3060-9. doi: 10.1158/1078-0432.CCR-08-0126.


IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C.

Blood. 2007 Nov 1;110(9):3192-201. Epub 2007 Jul 6.


The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.

Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J.

Clin Cancer Res. 2007 Apr 15;13(8):2471-8.

Supplemental Content

Loading ...
Support Center